clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Infant, Premature, Diseases D007235 7 associated lipids
Parkinson Disease D010300 53 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Influenza, Human D007251 11 associated lipids
Lymphadenitis D008199 8 associated lipids
Drug Eruptions D003875 30 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Synovitis D013585 15 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Renal Insufficiency D051437 8 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Insulin Resistance D007333 99 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Bacteremia D016470 9 associated lipids
Hemophilia A D006467 10 associated lipids
Encephalitis D004660 15 associated lipids
Barrett Esophagus D001471 3 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Rosacea D012393 13 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Helicobacter Infections D016481 21 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Hand Dermatoses D006229 5 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Ergotism D004881 4 associated lipids
Ecchymosis D004438 3 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Dyspepsia D004415 5 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Giardiasis D005873 3 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Prurigo D011536 4 associated lipids
Chlamydia Infections D002690 7 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Whooping Cough D014917 6 associated lipids
Urethritis D014526 9 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Fistula D005402 8 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Confusion D003221 4 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Iris Diseases D007499 2 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Ureteral Diseases D014515 3 associated lipids
IgA Deficiency D017098 2 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Soft Tissue Infections D018461 2 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Discitis D015299 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Periodontal Abscess D010508 2 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Psittacosis D009956 4 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Mycetoma D008271 4 associated lipids
Diphtheria D004165 2 associated lipids
Empyema D004653 3 associated lipids
Rickettsia Infections D012282 5 associated lipids
Sporotrichosis D013174 3 associated lipids
Pleural Diseases D010995 4 associated lipids
Bartonella Infections D001474 3 associated lipids
Lymphangitis D008205 4 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Isomoto H et al. Impact of Helicobacter pylori infection on gastric and plasma ghrelin dynamics in humans. 2005 Am. J. Gastroenterol. pmid:16086706
Pamuk ON et al. Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? 2000 Am. J. Gastroenterol. pmid:10926000
Sontag SJ et al. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin. 2001 Am. J. Gastroenterol. pmid:11374672
Kume K et al. Disappearance of both MALT lymphoma and hyperplastic polyps in the stomach after eradication of Helicobacter pylori. 2001 Am. J. Gastroenterol. pmid:11569719
al-Assi MT et al. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. 1994 Am. J. Gastroenterol. pmid:8053435
Take S et al. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. 2003 Am. J. Gastroenterol. pmid:14638340
de Bortoli N et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. 2007 Am. J. Gastroenterol. pmid:17313499
Chey WD and Wong BC American College of Gastroenterology guideline on the management of Helicobacter pylori infection. 2007 Am. J. Gastroenterol. pmid:17608775
Savarino V et al. What is the meaning of ranitidine in successful triple-therapy against Helicobacter pylori infection? 1995 Am. J. Gastroenterol. pmid:8540537
Froehlich F et al. Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. 2001 Am. J. Gastroenterol. pmid:11513170
Rokkas T et al. Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. 2006 Am. J. Gastroenterol. pmid:16928256
Sánchez-Delgado J et al. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. 2008 Am. J. Gastroenterol. pmid:18564109
Sugimoto M et al. Prevention of hemorrhage from intradiverticular ulcer in the duodenum by Helicobacter pylori eradication. 2000 Am. J. Gastroenterol. pmid:10685780
Vakil N H. pylori treatment: new wine in old bottles? 2009 Am. J. Gastroenterol. pmid:19098845
Rokkas T et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. 2009 Am. J. Gastroenterol. pmid:19098844
Lazzaroni M et al. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. 1997 Am. J. Gastroenterol. pmid:9128316
Sapone A et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. 2003 Am. J. Gastroenterol. pmid:12809821
van der Hulst RW et al. Therapeutic options after failed Helicobacter pylori eradication therapy. 1996 Am. J. Gastroenterol. pmid:8931413
Zhou L et al. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. 2014 Am. J. Gastroenterol. pmid:24642580
Sharma VK et al. A survey of gastroenterologists' perceptions and practices related to Helicobacter pylori infection. 1999 Am. J. Gastroenterol. pmid:10566709
Levy M et al. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. 2002 Am. J. Gastroenterol. pmid:11866264
Christopher K et al. Clarithromycin use preceding fulminant hepatic failure. 2002 Am. J. Gastroenterol. pmid:11866297
Narayani RI et al. Resolution of collagenous colitis after treatment for Helicobacter pylori. 2002 Am. J. Gastroenterol. pmid:11866305
Suzuki S et al. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. 2016 Am. J. Gastroenterol. pmid:27185079
Fennerty MB Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. 1998 Am. J. Gastroenterol. pmid:9448162
Sullivan B et al. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. 2002 Am. J. Gastroenterol. pmid:12385435
Labenz J and Börsch G Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers. 1995 Am. J. Gastroenterol. pmid:7733070
Gisbert JP et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. 2008 Am. J. Gastroenterol. pmid:17764498
Forné M et al. Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. 1995 Am. J. Gastroenterol. pmid:7733075
Giannini E et al. Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens. 2000 Am. J. Gastroenterol. pmid:11051345
Kim CG et al. Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial. 2008 Am. J. Gastroenterol. pmid:17714557
Zullo A et al. Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. 1997 Am. J. Gastroenterol. pmid:9362185
Sirimontaporn N et al. Ten-day sequential therapy of Helicobacter pylori infection in Thailand. 2010 Am. J. Gastroenterol. pmid:20010919
Basu PP et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. 2011 Am. J. Gastroenterol. pmid:21989146
Murata H et al. Evaluation of the PyloriTek test for detection of Helicobacter pylori infection in cases with and without eradication therapy. 1998 Am. J. Gastroenterol. pmid:9820380
Laine L et al. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. 1998 Am. J. Gastroenterol. pmid:9820381
Hasegawa T et al. Image of the month: Disseminated Nontuberculous Mycobacteriosis. 2015 Am. J. Gastroenterol. pmid:26673493
Schwartz H et al. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. 1998 Am. J. Gastroenterol. pmid:9576452
Bardhan KD et al. Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. 1998 Am. J. Gastroenterol. pmid:9517644
Adamek RJ et al. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. 1998 Am. J. Gastroenterol. pmid:9517645
Jarbol DE et al. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. 2006 Am. J. Gastroenterol. pmid:16771937
Bytzer P Management of the dyspeptic patient: anything goes? 2006 Am. J. Gastroenterol. pmid:16771938
Manes G et al. Eradication of Helicobacter pylori and dosages of esomeprazole. 2006 Am. J. Gastroenterol. pmid:16771971
Sonnenberg A et al. The effect of antibiotic therapy on bleeding from duodenal ulcer. 1999 Am. J. Gastroenterol. pmid:10201462
Smoot DT et al. Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. 1999 Am. J. Gastroenterol. pmid:10201463
Laine L et al. Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. 1999 Am. J. Gastroenterol. pmid:10201465
Nakao K et al. Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. 1997 Am. J. Gastroenterol. pmid:9177520
Maconi G et al. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? 2001 Am. J. Gastroenterol. pmid:11232676
Kadayifçi A et al. Low dose clarithromycin plus omeprazole eradicates Helicobacter pylori in duodenal ulcer disease. 1995 Am. J. Gastroenterol. pmid:7872307
Veldhuyzen van Zanten S et al. Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. 2003 Am. J. Gastroenterol. pmid:14499772